Andrew Pavia, M.D.
Andrew Pavia M.D. is the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases and adjunct Professor of Medicine at the University of Utah. He also serves as Director of Hospital Epidemiology at Primary Children's Medical Center and Associate Director of the Antimicrobial Stewardship Program.
He received his MD from Brown University and was a resident and Chief resident in Medicine at Dartmouth. He served as an EIS officer and Preventive Medicine Resident at CDC where he worked on diarrheal disease and HIV. He did Pediatric and Adult ID fellowship at the University of Utah.
His research interests have been wide ranging tied together by a focus on emerging infections. His work has focused on seasonal and pandemic influenza, respiratory infections and diagnostics, biodefense and bioterrorism, and antimicrobial stewardship HIV disease, diarrheal diseases.
He is the author of over 200 peer-reviewed papers and 45 invited reviews, editorials and textbook chapters. He currently serves as an advisor to CDC and the Utah Department of Health on COVID-19, and is a member of the NIH COVID-19 Treatment Guidelines Panel. He is a member of the National Academy of Science, Engineering and Medicine (formerly known as the IOM) Preparedness Forum. He co-chairs the Influenza Guidelines Writing Committee for the Infectious Disease Society of America (IDSA) and chaired the IDWeek Program Committee for 2018. He served for 6 years on the Board of Scientific Counselors for CDC and was recently an IDSA board member and chair of the IDSA Pandemic Influenza task force and the IDSA Public Health Committee. He has served on the National Vaccine Advisory Committee and the National Biodefense Science Board (NBSB) where he chaired the influenza working group during the 2009 H1N1 influenza pandemic.
Financial relationships
-
Attribution:SelfType of financial relationship:There are no financial relationships to disclose.Ineligible company:GlaxoSmithKlineTopic:Influenza testDate added:Date updated:08/19/2023
-
Attribution:SelfType of financial relationship:There are no financial relationships to disclose.Ineligible company:PfizerTopic:Early antiviral candidatesDate added:Date updated:08/19/2023